328 related articles for article (PubMed ID: 27988971)
1. Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: Does it work?
Vacha M; Chery G; Hulbert A; Byrns J; Benedetti C; Finlen Copeland CA; Gray A; Onwuemene O; Palmer SM; Snyder LD
Clin Transplant; 2017 Mar; 31(3):. PubMed ID: 27988971
[TBL] [Abstract][Full Text] [Related]
2. Durable renal response after combination of bortezomib, corticosteroids, rituximab, and plasmapheresis for late antibody-mediated renal transplant rejection
.
Ding Y; Francis J; Gautam A; Pelletier L; Sanchorawala V; Quillen K
Clin Nephrol; 2018 Apr; 89(4):252-259. PubMed ID: 29208204
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
4. Impacts of donor-specific anti-HLA antibodies and antibody-mediated rejection on outcomes after intestinal transplantation in children.
Petit LM; Rabant M; Canioni D; Suberbielle-Boissel C; Goulet O; Chardot C; Lacaille F
Pediatr Transplant; 2017 Mar; 21(2):. PubMed ID: 28084679
[TBL] [Abstract][Full Text] [Related]
5. Current challenges and opportunities in the management of antibody-mediated rejection in lung transplantation.
Hulbert AL; Pavlisko EN; Palmer SM
Curr Opin Organ Transplant; 2018 Jun; 23(3):308-315. PubMed ID: 29742565
[TBL] [Abstract][Full Text] [Related]
6. Impact of active antibody-mediated rejection treatment on donor-specific antibodies in pediatric kidney transplant recipients.
Kincaide E; Hitchman K; Hall R; Yamaguchi I; Ding Y; Crowther B
Pediatr Transplant; 2019 Dec; 23(8):e13590. PubMed ID: 31617318
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Mediated Rejection in Lung Transplantation: Clinical Outcomes and Donor-Specific Antibody Characteristics.
Roux A; Bendib Le Lan I; Holifanjaniaina S; Thomas KA; Hamid AM; Picard C; Grenet D; De Miranda S; Douvry B; Beaumont-Azuar L; Sage E; Devaquet J; Cuquemelle E; Le Guen M; Spreafico R; Suberbielle-Boissel C; Stern M; Parquin F;
Am J Transplant; 2016 Apr; 16(4):1216-28. PubMed ID: 26845386
[TBL] [Abstract][Full Text] [Related]
8. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
[TBL] [Abstract][Full Text] [Related]
9. Measurement of donor-specific HLA antibodies following plasma exchange therapy predicts clinical outcome in pediatric heart and lung transplant recipients with antibody-mediated rejection.
Jackups R; Canter C; Sweet SC; Mohanakumar T; Morris GP
J Clin Apher; 2013 Aug; 28(4):301-8. PubMed ID: 23426730
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection-a pilot study.
Slatinska J; Slavcev A; Honsova E; Hruba P; Kratochvilova I; Rohal T; Viklicky O
HLA; 2018 Dec; 92 Suppl 2():47-50. PubMed ID: 30168284
[TBL] [Abstract][Full Text] [Related]
11. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.
Morrow WR; Frazier EA; Mahle WT; Harville TO; Pye SE; Knecht KR; Howard EL; Smith RN; Saylors RL; Garcia X; Jaquiss RD; Woodle ES
Transplantation; 2012 Feb; 93(3):319-24. PubMed ID: 22179403
[TBL] [Abstract][Full Text] [Related]
12. Favorable Outcome of an Exclusively Posttransplant Prophylactic Strategy After Heart Transplantation in Recipients With High Immunological Risk.
Coutance G; d'Orio V; Belin L; Bréchot N; Saheb S; Lebreton G; Bouglé A; Rouvier P; Gautreau C; Ouldammar S; Chamillard X; Huot M; Amour J; Combes A; Leprince P; Varnous S
Transplantation; 2019 Jul; 103(7):1439-1449. PubMed ID: 30376551
[TBL] [Abstract][Full Text] [Related]
13. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
Stuckey LJ; Kamoun M; Chan KM
Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
[TBL] [Abstract][Full Text] [Related]
14. Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience.
Gheith O; Al-Otaibi T; Halim MA; Mahmoud T; Nair P; Monem MA; Al-Waheeb S; Hassan R; Nampoory N
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):150-155. PubMed ID: 28260457
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies.
Courtwright AM; Cao S; Wood I; Mallidi HR; Kawasawa J; Moniodis A; Ng J; El-Chemaly S; Goldberg HJ
Ann Am Thorac Soc; 2019 Sep; 16(9):1131-1137. PubMed ID: 31026404
[No Abstract] [Full Text] [Related]
16. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
17. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of combination therapy including rituximab for antibody-mediated rejection after lung transplantation.
Yamanashi K; Chen-Yoshikawa TF; Hamaji M; Yurugi K; Tanaka S; Yutaka Y; Yamada Y; Nakajima D; Ohsumi A; Date H
Gen Thorac Cardiovasc Surg; 2020 Feb; 68(2):142-149. PubMed ID: 31435872
[TBL] [Abstract][Full Text] [Related]
19. Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation.
Islam AK; Sinha N; DeVos JM; Kaleekal TS; Jyothula SS; Teeter LD; Nguyen DTM; Eagar TN; Moore LW; Puppala M; Wong STC; Knight RJ; Frost AE; Graviss EA; Osama Gaber A
Clin Transplant; 2017 Aug; 31(8):. PubMed ID: 28658512
[TBL] [Abstract][Full Text] [Related]
20. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]